Novo Nordisk, Ypsomed and CagriSema
Over the last couple of years, Danish company Novo Nordisk (NYSE: NVO) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's ...
With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...
The first prescription for the drug in China will reportedly be issued at a public hospital in Shanghai this week and will ...
LONDON, Nov 14 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing ...
Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. StockNews.com raised shares ...
Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at $155.00. Michael Nedelcovych has given his Buy rating ...
LONDON (Reuters) -Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback